Agios Pharmaceuticals, Inc. $546.3 Million Common Stock Offering

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 8,152,986 shares of common stock of Agios Pharmaceuticals, Inc. for approximately $546.3 million before underwriting discounts and estimated expenses of the offering.

Included in the shares are 1,063,433 shares sold by Agios pursuant to the underwriters’ exercise in full of their option to purchase additional shares. The common stock is listed on the NASDAQ Global Select Market under the symbol “AGIO.”

J.P. Morgan, Goldman Sachs & Co. LLC and Cowen acted as Joint Book-Running Managers and RBC Capital Markets, SunTrust Robinson Humphrey acted as Lead Managers.

Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. All Agios programs focus on genetically identified patient populations, leveraging its knowledge of metabolism, biology and genomics.

The Davis Polk capital markets team included partner Richard D. Truesdell Jr. (Picture) and associates Ferrell Maguire Keel and Jaryn S. Fields. The tax team included partner Michael Mollerus. Associates Bonnie Chen and Christopher C. Woller provided intellectual property and technology advice.

Involved fees earner: Richard Truesdell – Davis Polk & Wardwell; Ferrell Maguire Keel – Davis Polk & Wardwell; Jaryn Fields – Davis Polk & Wardwell; Michael Mollerus – Davis Polk & Wardwell; Bonnie Chen – Davis Polk & Wardwell; Christopher Woller – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Goldman, Sachs & Co.; JP Morgan; RBC Capital Markets; Cowen and Company; SunTrust Robinson Humphrey, Inc.;


Author: Ambrogio Visconti